# Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

> **NCT06780930** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Servier** · enrollment: 57 (actual)

## Conditions studied

- Residual or Recurrent Grade 2 IDH Mutant Glioma

## Interventions

- **DRUG:** Vorasidenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06780930
- **Lead sponsor:** Servier
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2025-10-02
- **Final completion:** 2030-10-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06780930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06780930, "Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06780930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*